ACI Panelists Discuss Misaligned Incentives in the Biosimilars Market
Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.
Adalimumab Biosimilar Transition Studies Reported at ECCO'21 Congress
Presentations at the European Crohn's and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.
Truxima Produces Savings and Comparable Outcomes for UK Patients With CLL, NHL
Investigators reported high overall response rates and savings of roughly $1400 per patient across cohorts.
Budget Model Predicts Savings for Switch to Rituximab Biosimilar in NHL, CLL
Sizeable savings per patient with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) were anticipated by a Medicare savings model.
Amgen Executive Weighs the Challenges for Interchangeable Biosimilars
A turning point for interchangeable biosimilars has arrived, as the first may be approved this year, but many questions about these agents have yet to be answered, according to Laura Sim, senior counsel for Amgen.
Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?
Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.
Pharmaceutical Pay-for-Delay Settlements "Have a Good Side"
Pay-for-delay settlements between drug companies are better regulated than in the past and are in danger of being overregulated, one panelist said.
Safety Findings Are Reported for Trastuzumab Biosimilars
Real-world evidence from Poland and Brazil confirms comparable safety for the trastuzumab biosimilars Kanjinti and Zedora in the breast and gastrointestinal cancer settings.
Investigators: Same-Day Pegfilgrastim Is Safe and Effective in Patients Receiving CTX for Breast, Lung Cancer
Same-day pegfilgrastim to combat febrile neutropenia in conjunction with myelosuppressive chemotherapy (CTX) is safe, investigators conclude.
Celltrion Reports Positive Real-World Findings for Truxima in DLBCL
Postmarketing retrospective studies of the rituximab biosimilar (CT-P10, Truxima) demonstrated comparable safety and efficacy for treatment of diffuse large B-cell lymphoma (DLBCL).
Study: OCM Reduces Use of Some Supportive Care Medications and Boosts Filgrastim Biosimilar Use
Investigators noted a reduction in use of high-cost supportive care agents, suggesting that the value-based Oncology Care Model (OCM) is working.
Ogivri Equivalence Demonstrated in Neoadjuvant HER2+ Comparative Trial
Investigators further elucidate the equivalence of a trastuzumab biosimilar vs Herceptin in human epidermal growth factor receptor 2–positive (HER2+) breast cancer.
Study Suggests Oncologists' Use of Biosimilars Grew From Trickle to Flood
When biosimilars emerged in oncology, oncologists dipped in a toe and then got serious, according to a retrospective study on usage and savings presented at ASCO 2021.
Texas Oncology Reports Savings From Biosimilar Substitution Effort
The substitution program was carried out in 2020 and yielded savings of $4 million in 1 month, investigators reported at ASCO 2021.
Etanercept Reverse Switching Is Measured in Netherlands Study
Investigators in the Netherlands observed that 13.7% of patients with rheumatic disease had switched back to etanercept originator at 4.4 years from baseline.
French Investigators Report Rituximab Immunogenicity Findings
Immunogenicity was rare but concerning for patients who switched from originator rituximab to the biosimilar Riximyo, investigators reported.
Poster Roundup: Results Presented for Samsung Bioepis Biosimilars for Adalimumab, Infliximab
Real-world clinical data compiled for patients with autoimmune disorders were presented at EULAR 2021.
Celltrion Supports High-Concentration Adalimumab Biosimilar Launch With Phase 3 Trial Data
Celltrion announces the launch timing for its much anticipated high-concentration formulation of adalimumab and presents trial data supporting equivalence to the reference product.
Pharmacy Economist Describes Fork in the Road for Generics and Biosimilars
Biosimilar manufacturers may encounter roadblocks in the months and years ahead, and generics manufacturers will find they've hit a ceiling, according to Adam Fein, PhD, CEO of the Drug Channels Institute.
Study Evaluates Insulin Availability in the Philippines
There is low insulin availability in the Philippines and investigators recommend policy and regulatory reviews.
Medicines for Europe Panel Targets Inefficiencies, Need for Education
More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.
Infliximab Study Yields Evidence of Biosimilar Equivalence
Adjusting for variables, investigators found little difference in disease outcomes for patients who switched to the infliximab originator vs biosimilars.
AbbVie Study Highlights Switching Costs for Rheumatic Biosimilars
A study funded by AbbVie finds support for maintaining patients on originator rheumatic agents, such as Humira (adalimumab), rather than switching to biosimilars.
Kaiser Permanente Investigators Confirm Mvasi Safety and Efficacy in Population With Nonsquamous NSCLC
The retrospective, real-world study (N = 353) conducted within the Kaiser Permanente network followed the July 2019 launch of the bevacizumab biosimilar Mvasi.
German Study Calculates Adalimumab Biosimilar Savings From Earlier Intervention
Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).
US, EU Regulators Discuss Tailoring Biosimilar Approvals
During a talk at the Medicines for Europe Biosimilar Medicines Conference, US and EU regulators discuss the potential for tailored approach to bring biosimilars to market sooner with less expense and wasted effort.
Regulators Look Back on 15 Years of Biosimilars in Europe
Advances in analytical testing have improved confidence in biosimilars, according to a Medicines for Europe panel.
Cyltezo Is a Contender for First Interchangeable to Humira, Boehringer Ingelheim Says
The results of Voltaire-X could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.
Kaiser Permanente Study Demonstrates Equivalence for Mvasi
Investigators tapped health system data to conduct an observational, real-world comparison of bevacizumab (Mvasi) vs the reference product (Avastin).
Medicines for Europe Panel Tackles Biosimilar Uptake
The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.